Management Team

Andrew D. Goldberg, MD, was appointed Chief Executive Officer of Achieve Life Sciences in April 2026. Dr. Goldberg is a physician, healthcare investor, and governance leader who has spent his career at the intersection of clinical medicine and commercial execution. Most recently, he served as a Portfolio Manager at Marshall Wace and previously as a Partner at Vivo Capital, a healthcare-focused investment firm. Earlier in his career, he was a consultant at McKinsey & Company in Silicon Valley, advising pharmaceutical, biotechnology, and medical device companies. He has served as a board director or observer at 19 life sciences companies, including Tarsus Pharmaceuticals (Nasdaq: TARS) through FDA approval and the national launch and commercialization of XDEMVY, Veradermics (NYSE: MANE) through its successful IPO, Inquis Medical through FDA approval and commercialization of the Aventus thrombectomy system, Elektrofi through its $900M acquisition by Halozyme Therapeutics (Nasdaq: HALO), Parse Biosciences through its acquisition by Qiagen (NYSE: QGEN), and Forge Biologics through its acquisition by Ajinomoto. As lead investor, he anchored the U.S. market transition for Verona Pharma (Nasdaq: VRNA), culminating in the $10.8B acquisition by Merck, and led the pre-IPO investment in Harmony Biosciences (Nasdaq: HRMY), which scaled WAKIX into a new category in sleep medicine. Dr. Goldberg is among the first physicians in the United States to earn dual board certification in Critical Care Medicine and Emergency Medicine. He served as an Instructor in Medicine at the Mayo Clinic, where he completed a Critical Care fellowship, after training in Emergency Medicine at LAC+USC. He has over 25 scientific publications including research on tobacco advertising, published in JAMA, that examined youth targeting and contributed to public-health initiatives that earned him the Oregon Governor's Council Outstanding Achievement Award. Dr. Goldberg received his MD from The George Washington University School of Medicine and a post-doctoral diploma in translational science from the Mayo Graduate School.

Erik Atkisson is the Chief Legal Officer at Achieve Life Sciences, bringing over 25 years of experience in the pharmaceutical and biotechnology industries. Mr. Atkisson has deep expertise in guiding the global development, launch, and commercialization of biopharmaceutical products, and has held senior legal positions at multiple clinical- and commercial-stage biopharmaceutical companies. Prior to Achieve, Mr. Atkisson served as General Counsel, Corporate Secretary, and Chief Compliance Officer at Rain Oncology, leading all legal matters including governance, IP, contracting, regulatory, privacy, and litigation. Earlier in his career, Mr. Atkisson served as General Counsel of Eiger BioPharmaceuticals and Chief Compliance Officer of Cytokinetics. He also held senior positions at Amneal Pharmaceuticals (formerly Impax Laboratories) and BioMarin Pharmaceutical. Mr. Atkisson holds a J.D. from Georgetown University Law Center, an M.Sc. from the University of Edinburgh, and a B.A. from Harvard University.

Mr. Oki has served as our Chief Financial Officer since December 2024. From January 2022 to November 2024, Mr. Oki served as Chief Financial Officer of Aytu Biopharma, Inc., a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products. From 2015 through January 2022, Mr. Oki served as Chief Financial Officer of Vivus LLC (formerly Vivus Inc.), a commercial-stage pharmaceutical company formerly listed on Nasdaq. From 2006 to 2015, Mr. Oki held several positions at Alexza Pharmaceuticals, Inc., a publicly listed specialty pharmaceutical company, most recently as Senior Vice President, Finance, Chief Financial Officer and Secretary. Before Alexza, Mr. Oki held roles of increasing responsibility at Pharmacyclics, Inc. and Incyte Genomics, Inc. (now Incyte Corporation), both life sciences companies. Mr. Oki began his career in public accounting at Deloitte & Touche, LLP (now Deloitte). Mr. Oki received his degree in Business Administration – Accounting and graduated with honors from San Jose State University and is a Certified Public Accountant (inactive).

Dr. Mark L. Rubinstein is the Chief Medical Officer at Achieve Life Sciences, bringing more than two decades of experience in clinical medicine, scientific research and medical affairs leadership, with a strong focus on nicotine cessation and preventive medicine. Prior to joining Achieve, Dr. Rubinstein served as the Head of Medical Affairs at Blip, where he spearheaded the company’s strategy to help smokers and vapers quit through FDA-approved medications and digital support tools. He was also Vice President of Global Scientific Affairs at Juul Labs, where he led efforts to prevent youth usage of nicotine products. He is Professor Emeritus of Pediatrics at the University of California, San Francisco (UCSF), where his NIH-funded research advanced understanding of adolescent nicotine addiction and smoking cessation interventions. Dr. Rubinstein earned his M.D. from Yale School of Medicine, completed his Internal Medicine residency at Yale–New Haven Hospital, and is board certified in Internal Medicine and Adolescent Medicine.

Gloria Cosgrove joined Achieve Life Sciences in July 2026 as Senior Vice President, Global Quality. Gloria brings more than 30 years of Quality leadership experience across the biotechnology and pharmaceutical industries, helping companies build scalable, phase-appropriate Quality organizations and Quality Management Systems that support products from early clinical development through commercialization. Prior to joining Achieve, Ms. Cosgrove served as a strategic Quality consultant (SVP) to Bicara Therapeutics, helping shape the company's Quality strategy and organizational structure as it advanced late-stage clinical development and prepared for future commercialization. She also served as Senior Vice President of Quality and later Senior Vice President of Quality & Technical Operations at Lyra Therapeutics. Prior to Lyra, Ms. Cosgrove served as Vice President of Global Quality at Seres Therapeutics, where she helped lead the company through FDA approval of the first microbiome therapeutic, VOWST™, while building a scalable Quality organization to support commercial manufacturing. Earlier in her career, she held a variety of Quality leadership roles at Boehringer Ingelheim, Regeneron Pharmaceuticals, and Synageva BioPharma. Ms. Cosgrove attended Utah State University and University of Bridgeport majoring in Special Education and Psychology.

Ronald Dadino joined Achieve Life Sciences in July 2026 as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain. Mr. Dadino brings over 40 years of CMC and operations experience, with deep expertise in drug substance and drug product development, product commercialization and clinical/commercial product supply chains. Prior to joining Achieve, Mr. Dadino was Executive Vice President, CMC and Supply Chain at Sling Therapeutics, where he was responsible for all pharmaceutical product development and the global clinical supply chain. He has also held a variety of executive management positions in both large and small pharmaceutical companies, as well as consulting for CMC related projects. Mr. Dadino has a diverse background in CMC including product development and commercialization, technical operations and commercial manufacturing. Mr. Dadino holds a B.S. in Pharmacy from the Philadelphia College of Pharmacy and Science and an M.S. in Pharmaceutical Quality Assurance/Regulatory Affairs from Temple University.

Mark Zappia joined Achieve Life Sciences in May 2026 as Senior Vice President, Commercial, focused on sales, commercial operations, and market access. Mr. Zappia brings nearly 20 years of commercial operations and finance leadership experience in specialty pharmaceuticals, with deep expertise in pre-commercial and launch strategy, commercial operations, and building commercial organizations from the ground up. Prior to joining Achieve, Mr. Zappia was Vice President, Commercial Operations at Verona Pharma, where he was one of three original commercial leaders who built the commercial operations function and helped drive the launch of Ohtuvayre®, one of the best pulmonary launches in the history of pharma. Before that, he held a series of commercial strategy and finance leadership roles at Mayne Pharma, including VP Commercial Strategy. Earlier in his career, Mr. Zappia held commercial operations, analytics, and finance roles at Circassia, Bioventus, and Sunovion Pharmaceuticals, building broad experience across respiratory, medical device, and CNS markets. Mr. Zappia holds an M.S. in Finance from Brandeis University and a B.S. in Accounting from Hartwick College.